Limits...
Olopatadine ophthalmic solution suppresses substance P release in the conjunctivitis models.

Tamura T - Asia Pac Allergy (2012)

Bottom Line: We investigated that the effect of olopatadine hydrochloride ophthalmic solutions (olopatadine 0.1% and olopatadine 0.2%) on rat conjunctivitis models compared with other anti-allergic ophthalmic solutions.The inhibitory effects by olopatadine were more potent than by other tested anti-allergic ophthalmic solutions.These results indicate that olopatadine ophthalmic solutions appear to exert additional SP release inhibition besides dual-action such as selective histamine H1 receptor antagonistic action and mast cell stabilization action.

View Article: PubMed Central - PubMed

Affiliation: Marketing Department Sales & Marketing Division and Pharmacological Research Laboratories, Research Division, Kyowa Hakko Kirin Co., Ltd., Tokyo 100-8185, Japan.

ABSTRACT

Background: Olopatadine hydrochloride ophthalmic solutions are treated for allergic conjunctival diseases that are a selective histamine H1 receptor antagonist and an inhibitor of the release of mediators including histamine from the human mast cells. Substance P (SP) levels are increased in tears of patients with allergic conjunctivitis. However, little is known about the regulation of SP release by anti-allergic ophthalmic solutions.

Objective: We investigated that the effect of olopatadine hydrochloride ophthalmic solutions (olopatadine 0.1% and olopatadine 0.2%) on rat conjunctivitis models compared with other anti-allergic ophthalmic solutions.

Methods: Conjunctivitis was induced by subconjunctival injection of histamine or intravenous injection of ovalbumin in rats passively sensitized with anti-ovalbumin anti-serum. The releases of SP were determined in the conjunctiva and tears using rat antigen-induced conjunctivitis models.

Results: Olopatadine 0.1% and 0.2% significantly inhibited the increased conjunctival dye leaked in the histamine- or antigen-induced hyperpermeability. The inhibitory effects by olopatadine were more potent than by other tested anti-allergic ophthalmic solutions. Moreover, olopatadine significantly inhibited the release of SP from the conjunctiva.

Conclusion: These results indicate that olopatadine ophthalmic solutions appear to exert additional SP release inhibition besides dual-action such as selective histamine H1 receptor antagonistic action and mast cell stabilization action.

No MeSH data available.


Related in: MedlinePlus

Effects of olopatadine ophthalmic solution 0.1% and 0.2% on ovalbumin-induced conjunctival vascular hyperpermeability in passively sensitized rats. Olopatadine ophthalmic solution 0.1% (olopatadine 0.1%), olopatadine ophthalmic solution 0.2% (olopatadine 0.2%) were applied topically onto the eyes 24 h, 6 h prior to the challenge of antigen, and 5 min after the challenge of antigen. Each column and vertical bar represents the mean ± SE of 4-7 rats. ***p < 0.001: significantly different from the control group (Student's t-test). ###p < 0.001: significantly different from the control group (Aspin Welch test).
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC3345324&req=5

Figure 2: Effects of olopatadine ophthalmic solution 0.1% and 0.2% on ovalbumin-induced conjunctival vascular hyperpermeability in passively sensitized rats. Olopatadine ophthalmic solution 0.1% (olopatadine 0.1%), olopatadine ophthalmic solution 0.2% (olopatadine 0.2%) were applied topically onto the eyes 24 h, 6 h prior to the challenge of antigen, and 5 min after the challenge of antigen. Each column and vertical bar represents the mean ± SE of 4-7 rats. ***p < 0.001: significantly different from the control group (Student's t-test). ###p < 0.001: significantly different from the control group (Aspin Welch test).

Mentions: Next, the onset and duration of action of olopatadine on the conjunctival vascular hyperpermeability were investigated in rat AC (Fig. 2). Ophthalmic solutions were applied topically onto eyes 24 h or 6 h prior to the challenge of antigen, or 5 min after the challenge of antigen. Pre-treatment 6 h with olopatadine 0.1% and 0.2% significantly inhibited the increased conjunctival dye leaked by 75.7% and 89.2% inhibition (p < 0.0001, p < 0.0001). Pre-treatment 24 h with olopatadine 0.1% and 0.2% significantly inhibited the increased conjunctival dye leaked by antigen by 71.6% and 80.4% inhibition (p = 0.0001, p = 0.0003). Moreover, when ophthalmic solutions were applied to the eyes 5 min after the challenge of antigen, olopatadine 0.1% and 0.2% also significantly inhibited the increased conjunctival dye leaked by 59.7% and 77.8% (p = 0.0006, p = 0.0002).


Olopatadine ophthalmic solution suppresses substance P release in the conjunctivitis models.

Tamura T - Asia Pac Allergy (2012)

Effects of olopatadine ophthalmic solution 0.1% and 0.2% on ovalbumin-induced conjunctival vascular hyperpermeability in passively sensitized rats. Olopatadine ophthalmic solution 0.1% (olopatadine 0.1%), olopatadine ophthalmic solution 0.2% (olopatadine 0.2%) were applied topically onto the eyes 24 h, 6 h prior to the challenge of antigen, and 5 min after the challenge of antigen. Each column and vertical bar represents the mean ± SE of 4-7 rats. ***p < 0.001: significantly different from the control group (Student's t-test). ###p < 0.001: significantly different from the control group (Aspin Welch test).
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC3345324&req=5

Figure 2: Effects of olopatadine ophthalmic solution 0.1% and 0.2% on ovalbumin-induced conjunctival vascular hyperpermeability in passively sensitized rats. Olopatadine ophthalmic solution 0.1% (olopatadine 0.1%), olopatadine ophthalmic solution 0.2% (olopatadine 0.2%) were applied topically onto the eyes 24 h, 6 h prior to the challenge of antigen, and 5 min after the challenge of antigen. Each column and vertical bar represents the mean ± SE of 4-7 rats. ***p < 0.001: significantly different from the control group (Student's t-test). ###p < 0.001: significantly different from the control group (Aspin Welch test).
Mentions: Next, the onset and duration of action of olopatadine on the conjunctival vascular hyperpermeability were investigated in rat AC (Fig. 2). Ophthalmic solutions were applied topically onto eyes 24 h or 6 h prior to the challenge of antigen, or 5 min after the challenge of antigen. Pre-treatment 6 h with olopatadine 0.1% and 0.2% significantly inhibited the increased conjunctival dye leaked by 75.7% and 89.2% inhibition (p < 0.0001, p < 0.0001). Pre-treatment 24 h with olopatadine 0.1% and 0.2% significantly inhibited the increased conjunctival dye leaked by antigen by 71.6% and 80.4% inhibition (p = 0.0001, p = 0.0003). Moreover, when ophthalmic solutions were applied to the eyes 5 min after the challenge of antigen, olopatadine 0.1% and 0.2% also significantly inhibited the increased conjunctival dye leaked by 59.7% and 77.8% (p = 0.0006, p = 0.0002).

Bottom Line: We investigated that the effect of olopatadine hydrochloride ophthalmic solutions (olopatadine 0.1% and olopatadine 0.2%) on rat conjunctivitis models compared with other anti-allergic ophthalmic solutions.The inhibitory effects by olopatadine were more potent than by other tested anti-allergic ophthalmic solutions.These results indicate that olopatadine ophthalmic solutions appear to exert additional SP release inhibition besides dual-action such as selective histamine H1 receptor antagonistic action and mast cell stabilization action.

View Article: PubMed Central - PubMed

Affiliation: Marketing Department Sales & Marketing Division and Pharmacological Research Laboratories, Research Division, Kyowa Hakko Kirin Co., Ltd., Tokyo 100-8185, Japan.

ABSTRACT

Background: Olopatadine hydrochloride ophthalmic solutions are treated for allergic conjunctival diseases that are a selective histamine H1 receptor antagonist and an inhibitor of the release of mediators including histamine from the human mast cells. Substance P (SP) levels are increased in tears of patients with allergic conjunctivitis. However, little is known about the regulation of SP release by anti-allergic ophthalmic solutions.

Objective: We investigated that the effect of olopatadine hydrochloride ophthalmic solutions (olopatadine 0.1% and olopatadine 0.2%) on rat conjunctivitis models compared with other anti-allergic ophthalmic solutions.

Methods: Conjunctivitis was induced by subconjunctival injection of histamine or intravenous injection of ovalbumin in rats passively sensitized with anti-ovalbumin anti-serum. The releases of SP were determined in the conjunctiva and tears using rat antigen-induced conjunctivitis models.

Results: Olopatadine 0.1% and 0.2% significantly inhibited the increased conjunctival dye leaked in the histamine- or antigen-induced hyperpermeability. The inhibitory effects by olopatadine were more potent than by other tested anti-allergic ophthalmic solutions. Moreover, olopatadine significantly inhibited the release of SP from the conjunctiva.

Conclusion: These results indicate that olopatadine ophthalmic solutions appear to exert additional SP release inhibition besides dual-action such as selective histamine H1 receptor antagonistic action and mast cell stabilization action.

No MeSH data available.


Related in: MedlinePlus